This is the authors' abstract. We don't add key points for this paper.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is rising globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome aggravation. We describe SARS-CoV-2-positive patients, two of whom were in a critical condition and one of whom was in a severe condition, who were administered favipiravir for their deteriorating conditions and cured.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: